Literature DB >> 29442576

Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs.

Ekaterini Christina Tampaki1,2, Athanasios Tampakis3, Raoul Droeser3,4, Efstratios Patsouris5, Gregory Kouraklis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29442576      PMCID： PMC6300348          DOI： 10.1080/15384047.2018.1433495

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  10 in total

Review 1.  The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?

Authors:  Vicki Plaks; Niwen Kong; Zena Werb
Journal:  Cell Stem Cell       Date:  2015-03-05       Impact factor: 24.633

2.  Cabozantinib in progressive medullary thyroid cancer.

Authors:  Rossella Elisei; Martin J Schlumberger; Stefan P Müller; Patrick Schöffski; Marcia S Brose; Manisha H Shah; Lisa Licitra; Barbara Jarzab; Viktor Medvedev; Michael C Kreissl; Bruno Niederle; Ezra E W Cohen; Lori J Wirth; Haythem Ali; Colin Hessel; Yifah Yaron; Douglas Ball; Barry Nelkin; Steven I Sherman
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

3.  Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma.

Authors:  Yao-An Shen; Chia-Yu Wang; Yi-Tao Hsieh; Yann-Jang Chen; Yau-Huei Wei
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

4.  Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy.

Authors:  J López-Erauskin; J Galino; M Ruiz; J M Cuezva; I Fabregat; D Cacabelos; J Boada; J Martínez; I Ferrer; R Pamplona; F Villarroya; M Portero-Otín; S Fourcade; A Pujol
Journal:  Hum Mol Genet       Date:  2013-04-20       Impact factor: 6.150

Review 5.  Ageing, oxidative stress and cancer: paradigms in parallax.

Authors:  Christopher C Benz; Christina Yau
Journal:  Nat Rev Cancer       Date:  2008-11       Impact factor: 60.716

Review 6.  Mitochondria in cancer stem cells: a target for therapy.

Authors:  Rute Loureiro; Katia A Mesquita; Paulo J Oliveira; Ignacio Vega-Naredo
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2013-05

7.  Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.

Authors:  Dmytro Starenki; Seung-Keun Hong; Pui-Kei Wu; Jong-In Park
Journal:  Cancer Biol Ther       Date:  2017-05-05       Impact factor: 4.742

Review 8.  EMT, CTCs and CSCs in tumor relapse and drug-resistance.

Authors:  Abhisek Mitra; Lopa Mishra; Shulin Li
Journal:  Oncotarget       Date:  2015-05-10

Review 9.  Bypassing Mechanisms of Mitochondria-Mediated Cancer Stem Cells Resistance to Chemo- and Radiotherapy.

Authors:  Alex Lyakhovich; Matilde E Lleonart
Journal:  Oxid Med Cell Longev       Date:  2015-11-30       Impact factor: 6.543

Review 10.  Management of advanced medullary thyroid cancer.

Authors:  Julien Hadoux; Furio Pacini; R Michael Tuttle; Martin Schlumberger
Journal:  Lancet Diabetes Endocrinol       Date:  2015-10-23       Impact factor: 32.069
  10 in total
  2 in total

1.  A Synthetic Small RNA Homologous to the D-Loop Transcript of mtDNA Enhances Mitochondrial Bioenergetics.

Authors:  Theodore L Mathuram; Danyelle M Townsend; Vincent J Lynch; Ilya Bederman; Zhi-Wei Ye; Jie Zhang; Wade J Sigurdson; Erin Prendergast; Raul Jobava; Jonathan P Ferruzza; Mary R D'Angelo; Maria Hatzoglou; Yaron Perry; Anna Blumental-Perry
Journal:  Front Physiol       Date:  2022-04-06       Impact factor: 4.755

2.  ERBB1- and ERBB2-Positive Medullary Thyroid Carcinoma: A Case Report.

Authors:  Michele Minuto; Emanuela Varaldo; Gianluca Marcocci; Amleto de Santanna; Ermanno Ciccone; Katia Cortese
Journal:  Diseases       Date:  2018-04-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.